JAZZ · Jazz Pharmaceuticals plc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Epidiolex/Epidyolex net product sales | $292M | 2Q26 | +16.0% |
|
|
|||
| Modeyso net product sales | $48M | 2Q26 | +9500.0% |
|
|
|||
| Non-GAAP adjusted earnings per share non-GAAP | $5.71 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted gross margin on total revenues non-GAAP | 92.1% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted net income non-GAAP | $396.4M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Xywav active idiopathic hypersomnia patients | 5,850 | 2Q26 | — |
|
|
|||
| Xywav active narcolepsy patients | 11,275 | 2Q26 | — |
|
|
|||
| Xywav active patients | 17,125 | 2Q26 | — |
|
|
|||
| Xywav net patient adds | 525 | 2Q26 | — |
|
|
|||
| Xywav net product sales | $471M | Three Months Ended June 30, 2026 | +13.4% |
|
|
|||
| Zepzelca net product sales | $106M | 2Q26 | +42.3% |
|
|
|||
| Ziihera net product sales | $15M | 2Q26 | — |
| Modeyso patients having received Modeyso since launch | 500 | from launch in August 2025 through the end of 1Q26 | — |
| active patients | 16,175 | 4Q25 | — |
| idiopathic hypersomnia (IH) patients | 5,225 | 4Q25 | — |
| narcolepsy patients | 10,950 | 4Q25 | — |
| net patient adds | 500 | 4Q25 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JAZZ
this stock
Jazz Pharmaceuticals plc
|
$15.90B | +44.1% | +8.8% | 16.7 | 5.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JAZZ | -4.5% | -1.0% | +41.4% | -3.1% | +44.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.9% | -5.5% | +27.6% | -7.0% | +30.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.